TY - JOUR
T1 - First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition
AU - Lin, Victor T.G.
AU - Nabell, Lisle M.
AU - Spencer, Sharon A.
AU - Carroll, William R.
AU - Harada, Shuko
AU - Yang, Eddy S.
N1 - Publisher Copyright:
© 2018 JNCCN - Journal of the National Comprehensive Cancer Network.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Salivary duct carcinoma (SDC) is a rare and aggressive malignancy for which limited data exist to guide treatment decisions. With the advent of advanced molecular testing and tumor genomic profiling, clinicians now have the ability to identify potential therapeutic targets in difficult-to-treat cancers such as SDC. This report presents a male patient with widely metastatic SDC found on targeted next-generation sequencing to have a BRAF p.V600E mutation. He experienced a prolonged and robust response to first-line systemic chemotherapy with dabrafenib and trametinib. During his response interval, new data emerged to justify subsequent treatment with both an immune checkpoint inhibitor and androgen blockade after his disease progressed. To our knowledge, this is the first report of frontline BRAF-directed therapy eliciting a response in metastatic SDC.
AB - Salivary duct carcinoma (SDC) is a rare and aggressive malignancy for which limited data exist to guide treatment decisions. With the advent of advanced molecular testing and tumor genomic profiling, clinicians now have the ability to identify potential therapeutic targets in difficult-to-treat cancers such as SDC. This report presents a male patient with widely metastatic SDC found on targeted next-generation sequencing to have a BRAF p.V600E mutation. He experienced a prolonged and robust response to first-line systemic chemotherapy with dabrafenib and trametinib. During his response interval, new data emerged to justify subsequent treatment with both an immune checkpoint inhibitor and androgen blockade after his disease progressed. To our knowledge, this is the first report of frontline BRAF-directed therapy eliciting a response in metastatic SDC.
UR - http://www.scopus.com/inward/record.url?scp=85054985403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054985403&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2018.7056
DO - 10.6004/jnccn.2018.7056
M3 - Article
C2 - 30323086
AN - SCOPUS:85054985403
SN - 1540-1405
VL - 16
SP - 1166
EP - 1170
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 10
ER -
